England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

Nivolumab is an antibody directed against programmed death 1 (PD-1) and is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma after previous platinum ...

Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared ...